Drugs / Haloperidol
Haloperidol
also known as
Haldol · Haloperidole · 18F-haloperidol · [19F]-HALOPERIDOL · Dolpin · Dozic · Fortunan · HAL · +15 more
Other / unclassified targets DRD2, HTR2A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | HALDOL | — | 1967-04-12 | fda.gov ↗ |
Trials 57 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04071639 | Mar 2020 → Dec 2024 | Huntington disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT03754062 | Jun 2017 → Sep 2019 | — | King's College London | Completed | No outcome recorded |
| Phase 1 | NCT01924468 | Aug 2013 → Sep 2018 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT01259973 | Feb → Nov 2011 | — | Hospital Clinic of Barcelona | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06218524 | Dec 2024 → Dec 2027 expected | glioblastoma | Southern Medical University, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04750395 | Sep 2021 → May 2024 | delirium | HCA Hospice Care | Unknown | No outcome recorded |
| Phase 2 | NCT00429676 | Dec 2005 → Sep 2007 | delirium | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT06168773 | Nov 2022 → Oct 2023 | delirium | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT05431595 | Jul 2022 → Feb 2027 expected | delirium, epilepsy | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03743649 | Jul 2019 → Dec 2028 expected | delirium, high grade malignant neoplasm, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03021486 | Jun 2017 → Jun 2021 overdue | delirium, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT02345902 | Jan 2016 → Mar 2018 | delirium | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Unknown | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT01811459 | Feb 2013 → Sep 2016 | delirium | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 3 | NCT01765829 | Nov 2012 → Nov 2015 | psychotic disorder | Fundación Pública Andaluza Progreso y Salud | Unknown | No outcome recorded |
| Phase 3 | NCT01211522 | Dec 2011 → Aug 2017 | delirium, mental disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00599287 | Feb → May 2008 | delirium | UMC Utrecht | Terminated | No outcome recorded |
| Phase 3 | NCT00300391 | Mar 2006 → Oct 2011 | delirium | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 3 | NCT00455234 | Sep 2005 → Jul 2006 | psychotic disorder | Christian Medical College, Vellore, India | Completed | No outcome recorded |
| Phase 3 | NCT00124930 | May 2005 → Jun 2008 | cancer or benign tumor | Alberta Health services | Terminated | No outcome recorded |
| Phase 3 | NCT00485901 | Jul 2004 → Jan 2005 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00000179 | — | Alzheimer disease | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 3 | NCT00189995 | — | schizophrenia | Beersheva Mental Health Center | Withdrawn | No outcome recorded |
| Phase 423 trials | ||||||
| Phase 4 | NCT07109245 | Dec 2025 → Aug 2028 expected | acute insulin response | Centre for Addiction and Mental Health | Recruiting | No outcome recorded |
| Phase 4 | NCT06395428 | Jul 2024 → Apr 2025 overdue | chronic pain syndrome | Western Michigan University School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT04764344 | Apr 2021 → May 2023 | — | Western Michigan University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT04176055 | Oct 2020 → Jun 2021 | cannabinoid hyperemesis syndrome | University of Calgary | Completed | No outcome recorded |
| Phase 4 | NCT03392376 | Jun 2018 → Jul 2022 | delirium | Zealand University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03199950 | Jun 2017 → Nov 2018 | delirium | Zuyderland Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT03056482 | May 2017 → Jun 2019 | cannabis dependence | Dr. Marco L.A. Sivilotti | Completed | No outcome recorded |
| Phase 4 | NCT02909465 | Jul 2016 → Apr 2017 | — | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02307396 | Feb 2015 → Jun 2016 | schizoaffective disorder, schizophrenia | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT02103881 | Apr → Jun 2014 | — | Hennepin Healthcare Research Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT02972502 | Feb 2014 → Apr 2017 | migraine disorder | OhioHealth | Terminated | No outcome recorded |
| Phase 4 | NCT02213900 | Sep 2013 → Dec 2015 | anxiety, delirium, depressive disorder, post-traumatic stress disorder | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT01785290 | Jun 2013 → Dec 2016 | delirium | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02057549 | Nov 2012 → Nov 2016 | gastroparesis | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| Phase 4 | NCT03489551 | Nov 2011 → Jul 2013 | delirium, disease related to hematopoietic stem cell transplant | Michelle Weckmann | Completed | No outcome recorded |
| Phase 4 | NCT01174290 | Sep 2010 → Aug 2013 | subacute delirium | Northeastern University | Completed | No outcome recorded |
| Phase 4 | NCT01016145 | Apr 2009 → Jun 2010 | psychotic disorder | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT01052389 | Jul 2007 → Jun 2012 | schizophrenia | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 4 | NCT00433121 | Sep 2006 → Aug 2007 | dementia | Innlandet Hospital Trust | Completed | No outcome recorded |
| Phase 4 | NCT00191555 | Aug 2003 → May 2006 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00159133 | Nov 2001 → Jun 2006 | schizophrenia | Heinrich-Heine University, Duesseldorf | Completed | No outcome recorded |
| Phase 4 | NCT00157378 | Nov 2000 → Dec 2004 | schizophrenia | Ludwig-Maximilians - University of Munich | Unknown | No outcome recorded |
| Phase 4 | NCT00159081 | Nov 2000 → Jun 2005 | schizophrenia | Heinrich-Heine University, Duesseldorf | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07087925 | Jan → Apr 2025 | — | Rully Riyandika | Completed | No outcome recorded |
| — | NCT02192723 | Jun 2012 → Jun 2014 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT01556932 | Mar 2012 → May 2013 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT01501123 | Nov 2011 → Oct 2015 | — | Catholic Health East | Completed | No outcome recorded |
| — | NCT03019887 | Apr 2011 → Jan 2017 | schizophrenia | Juntendo University | Completed | No outcome recorded |
| — | NCT01204255 | Nov 2010 → Apr 2011 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT01152697 | Jun 2010 → Aug 2012 | — | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| — | NCT00842608 | Feb 2009 → Jul 2015 | delirium | Indiana University | Completed | No outcome recorded |
| — | NCT00493233 | Nov 2006 → Dec 2008 | schizophrenia | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| — | NCT00625014 | Mar → Jul 2005 | hyperlipidemia | Leiden University Medical Center | Completed | No outcome recorded |
| — | NCT00018850 | Jun 1998 → Jun 2003 | schizophrenia | US Department of Veterans Affairs | Completed | No outcome recorded |
Also used as a comparator or background therapy in 79 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01684969 Comparator | Mar 2012 → May 2013 | — | Eric E. Prommer | Withdrawn | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01193621 Comparator | Jan 2008 → Jul 2010 | — | Asan Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02240173 Comparator | Jun → Dec 2017 | schizophrenia | Federal Neuro-Psychiatric Hospital, Yaba | Unknown | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT06428084 Comparator | Nov 2023 → Feb 2024 | gallbladder disorder | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT04715230 Comparator | Jun 2021 → Oct 2022 | methamphetamine-induced psychosis | InterveXion Therapeutics, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04529226 Comparator | Nov 2020 → Jan 2025 | intellectual disability, psychotic disorder | Andalusian Public Foundation for Health Research in Seville | Unknown | No outcome recorded |
| Phase 2 | NCT03375671 Comparator | May 2018 → Mar 2020 | — | David Barbic | Completed | No outcome recorded |
| Phase 2 | NCT01323205 Background | May 2011 → Nov 2012 | schizophrenia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02203786 Comparator | Sep 2009 → Jun 2015 | pathological gambling | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 2 | NCT00693472 Background | Aug 2007 → Dec 2008 | drug-induced akathisia, movement disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00505804 Comparator | Jan 2005 → Nov 2008 | delirium | Austin Health | Completed | No outcome recorded |
| Phase 2 | NCT00096863 Comparator | Dec 2004 → Jul 2007 | delirium | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT00044044 Comparator | Jul 2002 → May 2003 | schizophrenia | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00866645 Comparator | Feb 2009 → Jul 2010 | — | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00340379 Comparator | Apr 2003 → Aug 2005 | mood disorder | Duke University | Completed | No outcome recorded |
| Phase 321 trials | ||||||
| Phase 3 | NCT07246187 Comparator | Nov 2025 → Oct 2026 expected | cannabinoid hyperemesis syndrome | Mercy Bon Secours Saint Vincent Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06370442 Comparator | Jun 2024 → May 2025 | mental disorder | State University of New York - Upstate Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT05690698 Comparator | Apr → Jul 2023 | delirium | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT05803642 Comparator | Mar 2023 → May 2024 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04833023 Comparator | May 2022 → Dec 2024 | delirium | Tan Tock Seng Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05065567 Comparator | Aug 2021 → Nov 2023 | cyclic vomiting syndrome | Corewell Health South | Terminated | No outcome recorded |
| Phase 3 | NCT04081545 Background | Dec 2019 → Mar 2023 | substance-related disorder | Christine Oryhan | Completed | No outcome recorded |
| Phase 3 | NCT03628391 Comparator | Feb 2018 → Feb 2020 | delirium, psychotic disorder | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT02431702 Comparator | Jul 2015 → Nov 2019 | schizophrenia | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01862302 Comparator | Aug 2013 → Sep 2015 | — | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT01750541 Comparator | Dec 2012 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01140529 Comparator | May 2010 → May 2012 | delirium | Thorax-Kärlkliniken | Terminated | No outcome recorded |
| Phase 3 | NCT01081769 Comparator | Feb 2010 → Feb 2013 | schizophrenia | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT00954603 Comparator | Jun 2009 → Apr 2011 | delirium | Chiang Mai University | Terminated | No outcome recorded |
| Phase 3 | NCT00723606 Comparator | Sep 2008 → Jul 2009 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00797277 Comparator | Jul 2006 → Jun 2009 | schizoaffective disorder, schizophrenia | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00250237 Comparator | Nov 2005 → Nov 2008 | delirium | Bronovo Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00156065 Comparator | Sep 2005 → Sep 2007 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00156104 Comparator | Jul 2005 → Aug 2006 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00129220 Comparator | Jul 2005 → Jan 2009 | bipolar I disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00097266 Comparator | Dec 2004 → Jan 2007 | bipolar disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 429 trials | ||||||
| Phase 4 | NCT05246631 Comparator | Jan → Mar 2020 | — | Indonesia University | Completed | No outcome recorded |
| Phase 4 | NCT03639558 Comparator | Aug 2018 → Jul 2019 | — | Joseph Dib | Completed | No outcome recorded |
| Phase 4 | NCT03110900 Comparator | Sep 2017 → Apr 2018 | — | University of Arkansas | Terminated | No outcome recorded |
| Phase 4 | NCT03246620 Comparator | Sep 2017 → Jun 2018 | — | The University of Hong Kong | Terminated | No outcome recorded |
| Phase 4 | NCT03075657 Comparator | May 2017 → Jun 2018 | schizophrenia | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 4 | NCT02009306 Background | Jan 2017 → Feb 2018 | — | Gloucestershire Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT02747511 Comparator | Oct 2015 → Oct 2017 | migraine disorder | Western Michigan University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02493192 Comparator | Jul → Dec 2015 | — | Hospital General Universitario Gregorio Marañon | Unknown | No outcome recorded |
| Phase 4 | NCT02343575 Background | Jan 2015 → Jan 2018 | delirium | Stanford University | Terminated | No outcome recorded |
| Phase 4 | NCT02380118 Comparator | Dec 2014 → Sep 2019 | — | The University of Hong Kong | Terminated | No outcome recorded |
| Phase 4 | NCT02433041 Comparator | Jul 2013 → Dec 2018 | delirium | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT02098499 Comparator | Jun 2013 → Feb 2015 | migraine disorder | United States Naval Medical Center, Portsmouth | Withdrawn | No outcome recorded |
| Phase 4 | NCT02199743 Comparator | Feb 2013 → Jun 2016 | schizoaffective disorder, schizophrenia | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01530308 Comparator | Nov 2012 → Apr 2015 | delirium | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT01193166 Comparator | Aug 2010 → Sep 2012 | schizophrenia | Ortho-McNeil Janssen Scientific Affairs, LLC | Withdrawn | No outcome recorded |
| Phase 4 | NCT01161277 Comparator | Aug 2010 → Jun 2011 | schizophrenia | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01157351 Comparator | May 2010 → Dec 2013 | schizophrenia | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 4 | NCT01164059 Comparator | Feb 2010 → Aug 2013 | schizophrenia | University of Bremen | Completed | No outcome recorded |
| Phase 4 | NCT02143531 Comparator | Sep 2008 → Aug 2012 | — | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00786318 Comparator | Sep 2008 → Jul 2011 | delirium, psychotic disorder | George Washington University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00859872 Comparator | Aug 2008 → Mar 2009 | schizophrenia | Central South University | Completed | No outcome recorded |
| Phase 4 | NCT00838032 Comparator | Aug 2008 → May 2010 | schizophrenia | Sichuan University | Unknown | No outcome recorded |
| Phase 4 | NCT00457366 Comparator | May 2006 → Aug 2008 | — | University of Southern California | Completed | No outcome recorded |
| Phase 4 | NCT00767715 Comparator | Oct 2004 → Apr 2005 | bipolar disorder | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 4 | NCT00419653 Comparator | Jan 2003 → Sep 2007 | schizophrenia | University of Jena | Terminated | No outcome recorded |
| Phase 4 | NCT00009217 Comparator | Jan 1999 → Dec 2004 | Alzheimer disease, psychotic disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00007774 Comparator | Mar 1998 → Jun 2001 | schizoaffective disorder, schizophrenia | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00253110 Comparator | May 1996 → Sep 1998 | schizoaffective disorder, schizophrenia | Janssen, LP | Completed | No outcome recorded |
| Phase 4 | NCT00169091 Comparator | Mar 1996 → Sep 2003 | schizophrenia | Harvard Medical School (HMS and HSDM) | Terminated | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT06993194 Comparator | Jun 2025 → Jun 2026 overdue | delirium, traumatic brain injury | Benha University | Not yet recruiting | No outcome recorded |
| — | NCT06014606 Comparator | Mar 2021 → Apr 2023 | — | Maastricht University | Completed | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT01639599 Comparator | Mar → Dec 2012 | female reproductive system disorder | The Catholic University of Korea | Completed | No outcome recorded |
| — | NCT01539733 Comparator | Mar 2010 → Apr 2017 | cancer of unknown primary site, delirium | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01485692 Comparator | Feb 2009 → Mar 2011 | — | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT00753051 Comparator | Jun 2008 → Mar 2012 | schizophrenia | Khon Kaen University | Completed | No outcome recorded |
| — | NCT00833300 Comparator | Jun 2008 → Nov 2011 | delirium | Richard Hall | Terminated | No outcome recorded |
| — | NCT00642369 Comparator | Mar 2008 → Jul 2009 | schizophrenia | Guang Dong Provincial Mental Health Institute | Completed | No outcome recorded |
| — | NCT00631722 Comparator | May 2007 → Jan 2008 | schizophrenia | Peking University | Completed | No outcome recorded |
| — | NCT00534183 Comparator | Jun → Dec 2006 | diabetes mellitus, metabolic syndrome X, obesity disorder | Central Institute of Psychiatry, Ranchi, India | Completed | No outcome recorded |
| — | NCT00625170 Comparator | May → Dec 2004 | hyperlipidemia | Leiden University Medical Center | Completed | No outcome recorded |
| — | NCT00615797 Comparator | May 2002 → Dec 2009 | Sydenham chorea, post-bacterial disorder | University of Cape Town | Completed | No outcome recorded |
| — | NCT01123408 Comparator | Jun 1999 → Jul 2004 | schizophrenia | Nathan Kline Institute for Psychiatric Research | Completed | No outcome recorded |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 138 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | haloperidol | “Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol...” NCT01323205 ↗131“Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗ “In case of early signs of a relapse prodrome based early intervention with an antipsychotic drug (Haloperidol, Risperidone and other) vs. benzodiazepine (Lorazepam) was applied...” NCT00159133 ↗ “Patients randomized to oral comparator arm will receive oral antipsychotics (haloperidol, paliperidone ER, risperidone, olanzapine, quetiapine or aripiprazole) as per...” NCT01081769 ↗ “The investigators aim to study the effectiveness of Haloperidol compared with Olanzapine in the management of hyperactive delirium in advanced cancer or end-stage organ disease...” NCT04833023 ↗ “A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer” NCT00124930 ↗ “Patients received blindly olanzapine (5-20 mg/day; N=105), haloperidol (2.5-10 mg/day; N=20), or placebo (N=99) for 3 weeks.” PMID 22134043 ↗ Nov 2011 “Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks” NCT02192723 ↗ “ * Levomepromazine * Haloperidol Anti-emetic for nausea” NCT02009306 ↗ “-4mg dexamethasone, 1mg haloperidol, scopolamine patch” NCT04081545 ↗ “Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.” NCT01016145 ↗ “Drug: Haloperidol” NCT06370442 ↗ “haloperidol” NCT05246631 ↗ |
| Known as | 18F-haloperidol | “Intravenous 18F haloperidol(10 mCi)” NCT01193621 ↗ |
| Known as | [19F]-HALOPERIDOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | Dolpin | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | Dozic | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | Fortunan | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | HAL | “The role of dopamine (DA) was assessed by pre-treating participants with the D2 receptor (D2R)-preferring antagonist, haloperidol (HAL; 3-mg) or mixed D1R-D2R antagonist,...” PMID 36919514 ↗ Mar 2023 |
| Known as | Haldol | “The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have...” NCT00124930 ↗ |
| Known as | Haldol solutab | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | Haloperidol component of vesalium | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | Haloperidol decanoate impurity, haloperidol- | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | HALOPERIDOL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | Haloperidol Injection | “Drug: Haloperidol Injection” NCT06168773 ↗ |
| Known as | Haloperidol Tables, H31021234 | “Haloperidol Tables, H31021234” NCT04071639 ↗ |
| Known as | Haloperidole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00433121 ↗ |
| Known as | Kentace | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | Keselen | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | MCN-JR-1625 | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | Novo-peridol | “A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer” NCT00124930 ↗ |
| Known as | NSC-170973 | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | NSC-615296 | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | R-1625 | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | Serenace | ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗ |
| Known as | TEVA-HALOPERIDOL | “The oral investigational agent haloperidol (Generic Brand: TEVA-HALOPERIDOL) will be self-administered, at night, over 7 days.” NCT07109245 ↗ |
| Action | Inhibit | “Typical antipsychotics, like haloperidol, are dopamine antagonists” NCT01161277 ↗1“Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL54 ↗ |
| Modality | Other / unclassified | “haloperidol, a typical anti- psychotic” NCT04176055 ↗ |
| Route | Oral | “receive 20 weeks of open haloperidol treatment with an oral dose of 1-5 mg daily” NCT00009217 ↗ |
| Target | DRD2 | “DRD2 antagonist haloperidol” NCT06218524 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL54 ↗ |